Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 211 (Primary)
  • Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Germ cell cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Sarcoma; Solid tumours; Squamous cell cancer; Testicular cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors BioNTech

    • Most Recent Events

    • 04 Nov 2024 According to a BioNTech media release, In September 2024, data from the ongoing trial presented at ESMO showed signs of antitumor activity across indications.
    • 05 Aug 2024 According to a BioNTech media release, a data update is expected to be presented at the 2024 ESMO Congress.
    • 15 Feb 2024 Planned number of patients changed from 165 to 145.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top